Literature DB >> 26165249

Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis.

M D Di Taranto1, M N D'Agostino2, G Fortunato3.   

Abstract

AIMS: Familial Hypercholesterolemia (FH) is one of the most frequent dyslipidemias, the autosomal dominant form of which is primarily caused by mutations in the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, although in around 20% of patients the genetic cause remains unidentified. Genetic testing has notably improved the identification of patients suffering from FH, the most frequent cause of which is the presence of mutations in the LDLR gene. Although more than 1200 different mutations have been identified in this gene, about 80% are recognized to be pathogenic. We aim to overview the current methods used to perform the functional characterization of mutations causing FH and to highlight the conditions requiring a functional characterization of the variant in order to obtain a diagnostic report. DATA SYNTHESIS: In the current review, we summarize the different types of functional assays - including their advantages and disadvantages - performed to characterize mutations in the LDLR, APOB and PCSK9 genes helping to better define their pathogenic role. We describe the evaluation of splicing alterations and two major procedures for functional characterization: 1. ex vivo methods, using cells from FH patients; 2. in vitro methods using cell lines.
CONCLUSIONS: Functional characterization of the LDLR, APOB and PCSK9 mutant genes associated with FH can be considered a necessary integration of its genetic diagnosis.
Copyright © 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APOB; Diagnostic tools; Familial hypercholesterolemia; Functional assay; LDLR; Mutation pathogenicity; PCSK9

Mesh:

Substances:

Year:  2015        PMID: 26165249     DOI: 10.1016/j.numecd.2015.06.007

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  13 in total

1.  Characterization of two novel pathogenic variants at compound heterozygous status in lipase maturation factor 1 gene causing severe hypertriglyceridemia.

Authors:  Miklós Péterfy; Candy Bedoya; Carola Giacobbe; Carmen Pagano; Marco Gentile; Paolo Rubba; Giuliana Fortunato; Maria Donata Di Taranto
Journal:  J Clin Lipidol       Date:  2018-07-25       Impact factor: 4.766

Review 2.  Genetic susceptibility to cerebrovascular disease.

Authors:  David Della-Morte; Francesca Pacifici; Tatjana Rundek
Journal:  Curr Opin Lipidol       Date:  2016-04       Impact factor: 4.776

3.  Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports.

Authors:  Maria Donata Di Taranto; Monica Gelzo; Carola Giacobbe; Marco Gentile; Gennaro Marotta; Silvia Savastano; Antonio Dello Russo; Giuliana Fortunato; Gaetano Corso
Journal:  Metab Brain Dis       Date:  2016-05-26       Impact factor: 3.584

4.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

5.  Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.

Authors:  Maria Donata Di Taranto; Asier Benito-Vicente; Carola Giacobbe; Kepa Belloso Uribe; Paolo Rubba; Aitor Etxebarria; Ornella Guardamagna; Marco Gentile; Cesar Martín; Giuliana Fortunato
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

6.  Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study.

Authors:  Longina Kłosiewicz-Latoszek; Barbara Cybulska; Janina Białobrzeska-Paluszkiewicz; Anna Jagielska; Jolanta Janowska; Dorota Danowska; Anna Reguła; Małgorzata Stroniawska-Woźniak
Journal:  Arch Med Sci       Date:  2017-11-30       Impact factor: 3.318

7.  Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population.

Authors:  Khalid Khalaf Alharbi; May Salem Alnbaheen; Fawiziah Khalaf Alharbi; Rana M Hasanato; Imran Ali Khan
Journal:  Ann Saudi Med       Date:  2017 Nov-Dec       Impact factor: 1.526

8.  Preparation of a Functional Rat LDL Receptor Minigene.

Authors:  Catherine J Wooten; Dayami Lopez
Journal:  Int J Biomed Investig       Date:  2019-12-31

9.  Exhaustive Genome-Wide Search for SNP-SNP Interactions Across 10 Human Diseases.

Authors:  William Murk; Andrew T DeWan
Journal:  G3 (Bethesda)       Date:  2016-07-07       Impact factor: 3.154

10.  A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia.

Authors:  Maria Donata Di Taranto; Carola Giacobbe; Alessio Buonaiuto; Ilenia Calcaterra; Daniela Palma; Giovanna Maione; Gabriella Iannuzzo; Matteo Nicola Dario Di Minno; Paolo Rubba; Giuliana Fortunato
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.